SELLAS Life Sciences Group, Inc. (SLS) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
20/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinSLS / S&P 248.94% / 15.20% |
LoseSLS / S&P SLS unavailable / 15.00% |
LoseSLS / S&P -34.38% / 50.40% |
| 2026-Q11/3 |
WinSLS / S&P 12.20% / -4.33% |
LoseSLS / S&P SLS unavailable / 11.30% |
LoseSLS / S&P -39.47% / 27.70% |
| 2025-Q41/3 |
WinSLS / S&P 134.16% / 2.65% |
LoseSLS / S&P SLS unavailable / 9.00% |
LoseSLS / S&P -51.92% / 13.40% |
| 2025-Q30/3 |
LoseSLS / S&P -26.48% / 8.12% |
LoseSLS / S&P SLS unavailable / 4.61% |
LoseSLS / S&P -59.42% / 13.45% |
| 2025-Q21/3 |
WinSLS / S&P 102.78% / 10.94% |
LoseSLS / S&P SLS unavailable / 4.83% |
LoseSLS / S&P -65.22% / 10.63% |
| 2025-Q11/3 |
WinSLS / S&P 3.85% / -4.27% |
LoseSLS / S&P SLS unavailable / 4.98% |
LoseSLS / S&P -65.45% / 10.57% |
| 2024-Q40/3 |
LoseSLS / S&P -16.80% / 2.41% |
LoseSLS / S&P SLS unavailable / 5.25% |
LoseSLS / S&P -61.76% / 6.15% |
| 2024-Q30/3 |
LoseSLS / S&P 5.04% / 5.89% |
LoseSLS / S&P SLS unavailable / 5.89% |
LoseSLS / S&P -55.19% / 6.11% |
| 2024-Q21/3 |
WinSLS / S&P 17.82% / 4.28% |
LoseSLS / S&P SLS unavailable / 5.38% |
LoseSLS / S&P -40.65% / 5.12% |
| 2024-Q10/3 |
LoseSLS / S&P -4.72% / 10.56% |
LoseSLS / S&P SLS unavailable / 5.71% |
LoseSLS / S&P -33.33% / 5.59% |
| 2023-Q40/3 |
LoseSLS / S&P -35.37% / 11.69% |
LoseSLS / S&P -100.00% / 6.81% |
LoseSLS / S&P -39.01% / 7.78% |
| 2023-Q31/3 |
WinSLS / S&P 4.46% / -3.27% |
LoseSLS / S&P -100.00% / 7.52% |
LoseSLS / S&P -30.63% / -5.03% |
| 2023-Q21/3 |
WinSLS / S&P 9.79% / 8.74% |
LoseSLS / S&P -100.00% / 9.50% |
LoseSLS / S&P -33.48% / -8.57% |
| 2023-Q10/3 |
LoseSLS / S&P -39.41% / 7.50% |
LoseSLS / S&P -100.00% / 10.77% |
LoseSLS / S&P -25.68% / -15.69% |
| 2022-Q42/3 |
WinSLS / S&P 16.83% / 7.56% |
LoseSLS / S&P -86.84% / 11.88% |
WinSLS / S&P 67.67% / -17.99% |
| 2022-Q31/3 |
LoseSLS / S&P -9.42% / -4.88% |
LoseSLS / S&P -89.47% / 13.47% |
WinSLS / S&P 86.55% / -1.41% |
| 2022-Q21/3 |
LoseSLS / S&P -66.62% / -16.10% |
LoseSLS / S&P -89.47% / 13.71% |
WinSLS / S&P 83.46% / 11.04% |
| 2022-Q11/3 |
WinSLS / S&P 20.80% / -4.60% |
LoseSLS / S&P -61.84% / 15.97% |
LoseSLS / S&P 36.20% / 42.23% |
| 2021-Q41/3 |
LoseSLS / S&P -39.63% / 11.03% |
WinSLS / S&P 300.00% / 15.00% |
LoseSLS / S&P SLS unavailable / 96.40% |
| 2021-Q30/3 |
LoseSLS / S&P -17.48% / 0.58% |
LoseSLS / S&P SLS unavailable / 10.77% |
LoseSLS / S&P SLS unavailable / 69.42% |
| 2021-Q21/3 |
WinSLS / S&P 29.98% / 8.55% |
LoseSLS / S&P SLS unavailable / 6.58% |
LoseSLS / S&P SLS unavailable / 51.81% |
| 2021-Q11/3 |
WinSLS / S&P 46.99% / 6.17% |
LoseSLS / S&P SLS unavailable / -1.06% |
LoseSLS / S&P SLS unavailable / 7.39% |
| 2020-Q41/3 |
WinSLS / S&P 119.25% / 12.15% |
LoseSLS / S&P SLS unavailable / -3.72% |
LoseSLS / S&P SLS unavailable / -33.42% |
| 2020-Q30/3 |
LoseSLS / S&P -9.56% / 8.93% |
LoseSLS / S&P SLS unavailable / -2.04% |
LoseSLS / S&P SLS unavailable / -27.10% |
| 2020-Q21/3 |
WinSLS / S&P 69.36% / 20.54% |
LoseSLS / S&P SLS unavailable / -0.46% |
LoseSLS / S&P SLS unavailable / -27.11% |
| 2020-Q10/3 |
LoseSLS / S&P -59.77% / -19.60% |
LoseSLS / S&P SLS unavailable / 3.47% |
LoseSLS / S&P SLS unavailable / -14.75% |
| 2019-Q40/3 |
LoseSLS / S&P -28.33% / 9.07% |
LoseSLS / S&P SLS unavailable / 5.36% |
LoseSLS / S&P SLS unavailable / 2.99% |
| 2019-Q31/3 |
WinSLS / S&P 9.09% / 1.70% |
LoseSLS / S&P SLS unavailable / 5.02% |
LoseSLS / S&P SLS unavailable / 0.21% |
| 2019-Q20/3 |
LoseSLS / S&P -89.22% / 4.30% |
LoseSLS / S&P SLS unavailable / 6.64% |
LoseSLS / S&P SLS unavailable / 8.65% |
| 2019-Q10/3 |
LoseSLS / S&P -17.07% / 13.65% |
LoseSLS / S&P SLS unavailable / 8.12% |
LoseSLS / S&P SLS unavailable / 14.29% |
| 2018-Q41/3 |
WinSLS / S&P 0.82% / -13.52% |
LoseSLS / S&P SLS unavailable / 9.05% |
LoseSLS / S&P SLS unavailable / 18.23% |
| 2018-Q30/3 |
LoseSLS / S&P -64.33% / 7.71% |
LoseSLS / S&P SLS unavailable / 10.21% |
LoseSLS / S&P SLS unavailable / 19.06% |
| 2018-Q20/3 |
LoseSLS / S&P -0.87% / 3.43% |
LoseSLS / S&P SLS unavailable / 9.03% |
LoseSLS / S&P SLS unavailable / 14.46% |
| 2018-Q10/3 |
LoseSLS / S&P -55.77% / -0.76% |
LoseSLS / S&P SLS unavailable / 7.68% |
LoseSLS / S&P SLS unavailable / 12.46% |
| 2017-Q40/3 |
LoseSLS / S&P -25.71% / 6.64% |
LoseSLS / S&P SLS unavailable / 7.03% |
LoseSLS / S&P SLS unavailable / 13.82% |
| 2017-Q30/3 |
LoseSLS / S&P -39.66% / 4.48% |
LoseSLS / S&P SLS unavailable / 5.68% |
LoseSLS / S&P SLS unavailable / 17.57% |
| 2017-Q20/3 |
LoseSLS / S&P -4.92% / 3.09% |
LoseSLS / S&P SLS unavailable / 4.83% |
LoseSLS / S&P SLS unavailable / 17.74% |
| 2017-Q10/3 |
LoseSLS / S&P -68.56% / 6.07% |
LoseSLS / S&P SLS unavailable / 3.67% |
LoseSLS / S&P SLS unavailable / 13.32% |
| 2016-Q40/3 |
LoseSLS / S&P -72.29% / 3.82% |
LoseSLS / S&P SLS unavailable / 2.09% |
LoseSLS / S&P SLS unavailable / 7.05% |
| 2016-Q30/3 |
LoseSLS / S&P -25.53% / 3.85% |
LoseSLS / S&P SLS unavailable / 0.20% |
LoseSLS / S&P SLS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SLS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 692.19% | 20.78% |
| Annualized return | 692.19% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SLS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 62.33% | 83.14% |
| Annualized return | 10.17% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | SLS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.87% | 319.30% |
| Annualized return | -48.68% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |